86 related articles for article (PubMed ID: 33011913)
1. Comments on "Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma".
Granata V; Fusco R; Palaia R; Belli A; Petrillo A; Izzo F
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):954-955. PubMed ID: 33011913
[No Abstract] [Full Text] [Related]
2. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Bhutiani N; Li Y; Zheng Q; Pandit H; Shi X; Chen Y; Yu Y; Pulliam ZR; Tan M; Martin RCG
Ann Surg Oncol; 2020 Oct; 27(11):4348-4359. PubMed ID: 32681477
[TBL] [Abstract][Full Text] [Related]
3. Comment: Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
Jahangiri Y
J Vasc Interv Radiol; 2021 May; 32(5):765-766. PubMed ID: 33642157
[No Abstract] [Full Text] [Related]
4. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Lamarca A; Foster L; Valle JW; Satyadas T; Siriwardena A
ESMO Open; 2020 Oct; 5(5):e000633. PubMed ID: 33122352
[No Abstract] [Full Text] [Related]
6. Port-site metastasis of pancreatic adenocarcinoma following 'successful' completion of neoadjuvant chemoradiation using FOLFIRINOX.
Gaszynski R; Gray A; Merrett N
ANZ J Surg; 2020 May; 90(5):922-924. PubMed ID: 31578779
[No Abstract] [Full Text] [Related]
7. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Shirasu H; Todaka A; Omae K; Fujii H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Kobayashi M; Fukutomi A
Cancer Sci; 2019 Feb; 110(2):707-716. PubMed ID: 30447099
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Usón Junior PLS; Rother ET; Maluf FC; Bugano DDG
Clin Colorectal Cancer; 2018 Sep; 17(3):187-197. PubMed ID: 29615310
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
11. Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
de Liguori Carino N; O'Reilly DA; Siriwardena AK; Valle JW; Radhakrishna G; Pihlak R; McNamara MG
Eur J Surg Oncol; 2018 Oct; 44(10):1486-1493. PubMed ID: 30146253
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
13. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract][Full Text] [Related]
14. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
15. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
[TBL] [Abstract][Full Text] [Related]
16. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
17. [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Kang SH; Kim JI; Moon HS; Kim SH; Sung JK; Lee BS; Jeong HY
Korean J Gastroenterol; 2010 Jan; 55(1):26-32. PubMed ID: 20098064
[TBL] [Abstract][Full Text] [Related]
18. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Yu K
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
[No Abstract] [Full Text] [Related]
19. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer.
Lei F; Xi X; Rachagani S; Seshacharyulu P; Talmon GA; Ponnusamy MP; Batra SK; Bronich TK
J Control Release; 2021 Feb; 330():1229-1243. PubMed ID: 33217475
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
